Cogitars

Executive Summary

Cogitars, based in Munich, Germany, is a specialized statistical consulting firm focused on early-stage drug development. Founded in 2019, the company leverages expertise in adaptive Bayesian clinical trials to help biopharma clients optimize study designs, reduce trial costs, and accelerate decision-making. By applying Bayesian methods, Cogitars enables more efficient dose-finding, interim analyses, and seamless phase transitions. In an era where clinical trial costs are rising and regulatory agencies increasingly accept innovative designs, Cogitars’ niche in Bayesian statistics positions it as a valuable partner for small to mid-sized biotechs. While the company has not disclosed funding or revenue, its focus on a high-value, technical service segment suggests steady demand. The main risk is scalability and dependency on a small team of experts. Overall, Cogitars is well-placed to benefit from the growing adoption of adaptive trial designs in drug development.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership or multi-year consulting contract35% success
• Q4 2026Launch of proprietary software for Bayesian trial simulation45% success
• Q2 2026Publication of a landmark case study demonstrating cost savings with adaptive design60% success